Tekla Capital Management’s Myriad Genetics MYGN Stock Holding History

Tekla Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-18,805	Closed	-$512K	–	221
2019 Q4	$512K	Hold	18,805	–	–	0.02%	195
2019 Q3	$538K	Sell	18,805 -1,744	-8%	-$50.8K	0.02%	173
2019 Q2	$571K	Hold	20,549	–	–	0.02%	180
2019 Q1	$682K	Buy	+20,549	New	+$626K	0.03%	173
2015 Q3	–	Sell	-74,800	Closed	-$2.54M	–	167
2015 Q2	$2.54M	Hold	74,800	–	–	0.09%	97
2015 Q1	$2.65M	Sell	74,800 -37,400	-33%	-$1.34M	0.1%	103
2014 Q4	$3.82M	Hold	112,200	–	–	0.18%	76
2014 Q3	$4.33M	Buy	+112,200	New	+$4.19M	0.2%	86

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Tekla Capital Management's MYGN Position: Q1 2020 in Review

Tekla Capital Management sold out of Myriad Genetics (MYGN) in Q1 2020, closing a stake of 18,805 shares — an estimated $512K sold.

Tekla Capital Management first reported a position in MYGN in Q3 2014 and held it in 8 quarters. The position peaked at $4.33M in Q3 2014. 190 funds tracked by Wall St. Rank hold MYGN as of Q1 2020.

Tekla Capital Management reported no remaining Myriad Genetics position as of Q1 2020 after selling out during the quarter.
Tekla Capital Management sold 18,805 Myriad Genetics shares in Q1 2020, an estimated $512K.
Tekla Capital Management first reported a position in Myriad Genetics in Q3 2014 and held it in 8 quarters.
Tekla Capital Management's Myriad Genetics position peaked at $4.33M in Q3 2014.
190 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2020.

Based on Tekla Capital Management's 13F filing for Q1 2020, filed 14 May 2020.